Business Context and Reporting Period
Company: Repligen Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1995
Business Overview: Repligen is a biotechnology company focused on the clinical development of lead product candidates, specifically recombinant platelet factor-4 (rPF4) and anti-inflammation products. The company is currently undergoing a major restructuring to reduce expenditures and preserve cash.
Key Financial Metrics
| Metric | Q2 1995 | Q2 1994 |
|---|---|---|
| Total Revenues | $2,836,316 | $4,827,054 |
| Net Loss | $(2,638,620) | $(6,022,169) |
| Net Loss Per Share | $(0.17) | $(0.39) |
| Cash & Cash Equivalents | $7,588,041 | $29,371,325 (End of Period) |
| Marketable Securities | $4,012,263 | N/A (Not listed in Q2 1994 table) |
| Working Capital | $7,076,000 | $9,070,000 (Prior Quarter) |
| Debt | $0 (Term loan paid in May 1995) | $4,620,000 (Term loan outstanding) |
Liquidity: Total cash, cash equivalents, and marketable securities totaled approximately $11.6 million at June 30, 1995, a 24% decrease from the prior quarter. The company has no outstanding term loans as of the reporting date.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately $2.0 million (41%) compared to the prior year quarter. This was driven by reduced research and development funding from Eli Lilly and Company and Repligen Clinical Partners, L.P., as products entered clinical trials and funding needs shifted.
- Expense Reduction: Total expenses decreased by approximately $5.4 million (50%) year-over-year. This significant reduction is attributed to a major restructuring in fiscal 1995, which included severance costs, facility sublease losses, and asset write-offs.
- Improved Loss Position: While the company remains unprofitable, the net loss improved significantly from $6.0 million in Q2 1994 to $2.6 million in Q2 1995.
- Cash Flow: Operating cash flow turned negative, using $3.9 million in the quarter, compared to a positive $0.9 million in the prior year quarter. This was due to the net loss and changes in working capital, offset partially by the collection of amounts due from affiliates.
Outlook, Risks, and Management Commentary
- Capital Needs: Management estimates a need for approximately $60 million to complete the rPF4 research program, obtain regulatory approvals, and commence sales. Current funds are estimated to sustain operations only until March 31, 1996.
- Financing Risk: The filing explicitly states that without additional financing in calendar 1995 or early 1996 (via equity offering, third-party funding, or merger/acquisition), the company will be forced to curtail or cease operations.
- Lease Covenants: The company is in default of certain financial covenants in its equipment lease agreements (requiring minimum cash balances). This gives lessors the right to accelerate future lease payments totaling $5.2 million. Management is negotiating early termination and reduction of these obligations.
- Restructuring: A total restructuring charge of $11.3 million was recorded in fiscal 1995 ($975,000 in Q2 and $10.3 million in Q4). This included $6.5 million in cash expenditures for severance and lease payments.
- Partnership Status: Funding from Repligen Clinical Partners, L.P. is expected to continue into the fourth quarter of 1995 but at a reduced rate. The Partnership's working capital is $1.7 million.
Investor Verification Checklist
- Runway Confirmation: Verify if the company has secured the necessary financing to extend operations beyond the projected March 31, 1996 date.
- Lease Negotiations: Confirm the status of negotiations with equipment lessors regarding the $5.2 million in accelerated payments and whether a waiver or restructuring has been agreed upon.
- Partnership Funding: Monitor the cash flow from Repligen Clinical Partners, L.P., specifically the receipt of the remaining $1.76 million installment from limited partners.
- Product Development: Track the progress of the rPF4 and anti-inflammation programs through Phase I/II clinical trials, as this drives future revenue potential.
- Equity Dilution: Assess the likelihood and terms of any potential equity offering or merger, given the company's statement that a standalone offering sufficient to fund the program is not currently feasible.